Autoimmune diseases are among the most complex conditions to diagnose. Symptoms can be vague, overlap across conditions, and vary significantly from one patient to another.
For years, antinuclear antibody (ANA) testing has served as a standard starting point for diagnosis and treatment. However, ANA testing alone often falls short. These antibodies are not always present in autoimmune conditions and can also appear in individuals without disease - leading to inconclusive results, delayed diagnosis, and unnecessary referrals.
Primary care providers are often the first to recognize early signs of autoimmune disease. Having access to more comprehensive, clinically relevant testing at this stage can significantly improve the diagnostic journey.
Introducting ANAlyzeRTM
DLO offers a ANAlyzeRTM panel designed to improve a more complete picture. By combining multiple assays into a single test, ANAlyzeRTM evaluates 25 analytes using advanced methodologies, including IFA for ANA and dsDNA.
What this means for providers:
- Improved sensitivity and consistency
- Standardized reporting using ICAP nomenclature
- Fewer follow-up tests and visits
- More confidence in clinical decision making
Rather than relying on a single marker, ANAlyzeRTM delivers a broader, more actionable view - helping providers navigate complex autoimmune presentations with greater clarity. Because when it comes to autoimmune disease, earlier insights can make all the difference.
To learn more about ordering ANAlyzeRTM , reach out to your DLO Account Executive or fill out the Become A Client Form to get started with DLO.
